Zymeworks Announces Participation in Upcoming Investor Conferences

ZYME 11.21.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-12-03
Name of Upcoming Event:Piper Sandler 36th Annual Healthcare Conference
Date of Upcoming Event:2024-12-03
Name of Upcoming Event:Citi's 2024 Global Healthcare Conference
Date of Upcoming Event:2024-12-04
Name of Upcoming Event:7th Annual Evercore HealthCONx Conference
Date of Upcoming Event:2025-01-16
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
Date of Upcoming Event:2024-12-12
Name of Upcoming Event:Research & Development Day
Full Press ReleaseSEC FilingsOur ZYME Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.08.2025 - Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
  • 12.12.2024 - Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Recent Filings

    VANCOUVER, British Columbia,Nov. 21, 2024(GLOBE NEWSWIRE) --Zymeworks Inc.(Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:

    • Piper Sandler 36thAnnual Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and present onDecember 3at1:30 pm Eastern Time(ET) inNew York, NY.
    • Citi's 2024 Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a panel discussion titled: ‘Novel Antibody Mechanisms in Oncology’ onDecember 3at3:15 pm ETinMiami, FL.
    • 7thAnnualEvercore HealthCONx Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat onDecember 4at7:55 am ETinCoral Gables, FL.
    • 43rdAnnualJ.P. Morgan Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings onJanuary 13-16, 2025, and a corporate presentation onJanuary 16at8:15 am Pacific Time(PT) inSan Francisco, CA.

    In addition,Zymeworkswill present an update on its preclinical research programs at their Research & Development Day, taking place virtually and in-person onDecember 12, 2024, inNew York, NY. This event, led byPaul Moore, PhD, Zymeworks’ Chief Scientific Officer, will feature:

    • Updates on our portfolio of solid tumor targeting antibody-drug conjugates and T-cell Engager (TCE) molecules, featuring key opinion leaders from these therapeutic areas who will join the Company’s management team to discuss ongoing R&D and clinical activities;
    • Candidate nomination from our Trispecific TCE platform as the last product candidate in our '5 by 5' R&D strategy; and
    • Strategy and rationale for potential expansion into new therapeutic areas in hematological cancers and autoimmune and inflammatory diseases and preclinical development progress on potential investigational new drug applications for new product candidates in 2026 and beyond.

    To register your participation for Zymeworks’ Research & Development Day, pleaseclick here.

    AboutZymeworks Inc.

    Zymeworksis a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates.Zymeworksengineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary AzymetricTM technology.Zymeworkshas entered into separate agreements with BeiGene, Ltd. (BeiGene) andJazz Pharmaceuticals Ireland Limited(Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. TheU.S.FDA granted accelerated approval of Ziihera®(zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC). Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in theU.S.A BLA has also been accepted for review by theCenter for Drug Evaluation(CDE) of theNational Medical Products Administration(NMPA) inChina.Zymeworksis rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with investigational new drug applications for ZW220 and ZW251 planned for 2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information aboutZymeworks, visitwww.zymeworks.comand follow@ZymeworksIncon X.

    Contacts:

    Investor Inquiries:

    Shrinal InamdarDirector, Investor Relations(604) 678-1388ir@zymeworks.com

    Media Inquiries:

    Diana PapoveSenior Director, Corporate Communications(604) 678-1388media@zymeworks.com

    Primary Logo

    Source: Zymeworks Inc.

    Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com